New dopaminergic agonists

被引：0
|
作者：
De Mattos, JP [1 ]
Mattos, VMDC [1 ]
机构：
[1] Univ Fed Rio de Janeiro, Serv Neurol, Hosp Univ Clementino Fraga Filho, BR-21941 Rio De Janeiro, Brazil
来源：
ARQUIVOS DE NEURO-PSIQUIATRIA | 1999年 / 57卷 / 2A期
关键词：
levodopa; dopaminergic agonists; Parkinson's disease;
D O I：
10.1590/S0004-282X1999000200029
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
We present a brief review of the literature about dopaminergic a,agonists. We report the five known dopaminergic receptors, where they are located, the advantages and disadvantages of the employment in parkinsonian patients. The dopaminergic agonists were introduced to control the limitations of levodopa-increasing the therapheutic window. We analyse the pharmacocynetic efficacy and the side effects of cabergoline, ropinirole and pramipexole.
引用
收藏
页码：329 / 332
页数：4
相关论文
共 50 条
  • [31] Induced dopaminergic neurons: A new promise for Parkinson's disease
    Xu, Zhimin
    Chu, Xingkun
    Jiang, Houbo
    Schilling, Haley
    Chen, Shengdi
    Feng, Jian
    REDOX BIOLOGY, 2017, 11 : 606 - 612
  • [32] Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: A microdialysis study in the rat
    Silva, MAD
    Mattern, C
    Hacker, R
    Nogueira, PJC
    Huston, JP
    Schwarting, RKW
    JOURNAL OF NEUROCHEMISTRY, 1997, 68 (01) : 233 - 239
  • [33] MYTHS AND REALITIES OF CONTINUOUS DOPAMINERGIC STIMULATION
    Pirtosek, Zvezdan
    PSYCHIATRIA DANUBINA, 2011, 23 (01) : 80 - 83
  • [34] Continuous dopaminergic stimulation:: experimental evidence
    Marín, C
    NEUROLOGIA, 2002, 17 : 46 - 56
  • [35] CLINICAL IMPLICATIONS OF SUSTAINED DOPAMINERGIC STIMULATION
    STOCCHI, F
    PATSALOS, PN
    BERARDELLI, A
    BARBATO, L
    BONAMARTINI, A
    MANFREDI, M
    RUGGIERI, S
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 : S7 - S13
  • [36] Computational study on new natural compound agonists of dopamine receptor
    Li, Hui
    Yang, Wenzhuo
    Xi, Jianxin
    Wang, Zhenhua
    Lu, Han
    Du, Zhishan
    Li, Weihang
    Wu, Bo
    Jiang, Shanshan
    Peng, Yida
    Liu, Jingyi
    Liu, Luwei
    Zhang, Xiangheng
    Feng, Jiachun
    AGING-US, 2021, 13 (12): : 16620 - 16636
  • [37] Dopamine Receptor Agonists: New Formulations and New Potentials in the Treatment of Parkinson’s Disease
    Katunina E.A.
    Titova N.V.
    Bezdol’nyi Y.N.
    Shikkerimov R.K.
    Gasanov M.G.
    Burd S.G.
    Lebedeva A.V.
    Boiko A.N.
    Neuroscience and Behavioral Physiology, 2016, 46 (8) : 971 - 977
  • [38] Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions
    Kashihara, K
    Manabe, Y
    Murakami, T
    Abe, K
    LIFE SCIENCES, 2002, 70 (09) : 1095 - 1100
  • [39] Increased Lysosomal Exocytosis Induced by Lysosomal Ca2+ Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity
    Tsunemi, Taiji
    Perez-Rosello, Tamara
    Ishiguro, Yuta
    Yoroisaka, Asako
    Jeon, Sohee
    Hamada, Kana
    Rammonhan, Malini
    Wong, Yvette C.
    Xie, Zhong
    Akamatsu, Wado
    Mazzulli, Joseph R.
    Surmeier, D. James
    Hattori, Nobutaka
    Krainc, Dimitri
    JOURNAL OF NEUROSCIENCE, 2019, 39 (29) : 5760 - 5772
  • [40] Dopaminergic Neurotransmission in the Human Brain: New Lessons from Perturbation and Imaging
    Ko, Ji Hyun
    Strafella, Antonio P.
    NEUROSCIENTIST, 2012, 18 (02) : 149 - 168
12345